Blue Horizon focuses on using stem cells to treat a range of diseases and to provide health benefits without the use of drugs or surgery.
Global stem cell research and innovation company pioneering ethical, effective, and safe cord blood therapies.
Brian Mehling M.D. is the founder and Chief Medical Officer of BHI Therapeutic Sciences, Inc. Dr. Mehling is also a world-renowned orthopedic trauma surgeon whose mainstay of practice is in the greater New York City metropolitan area. He is a member of the prestigious International Society for Stem Cell Research. Dr. Mehling completed his residency in Orthopedic Surgery at The St. Joseph’s Hospital, Paterson, New Jersey and performed his fellowship in sports medicine at Graduate Hospital, Philadelphia, Pennsylvania. He is an alumnus of The Ohio State University and also holds a Master’s of Science Degree in Biochemistry. Dr. Mehling first conceived the Blue Horizon International Hospital concept (not owned by BHI Therapeutic Sciences, Inc.) while appraising differences in medical healthcare standards throughout Asia and the Middle East. Dr. Mehling recognized the truly significant need for universally high quality benchmarks in foreign nations and surmised that bringing the world’s best physicians to regions abroad would advance the standard of healthcare world-wide. In addition, American nationals traveling in foreign lands would be able to receive the same quality of healthcare they have grown to expect at home. In association with Blue Horizon International, BHI Therapeutic Sciences, Inc. plans to provide an opportunity for the U.S. community to participate in groundbreaking research while receiving stem cell therapy via state-of-the-art procedures provided in today’s western hospital safety conditions. Dr. Mehling is also a documentary film producer, debuting the film Tiny Tears at the prestigious Cannes Film Festival as well as a philanthropist, supporting many worthy causes dedicated to providing healthcare to children in impoverished areas.
BHI Therapeutic Sciences was formed with the mission to advance stem cell therapy in full regulatory conformance and in conjunction with the scientific community, while making stem cell therapy available to those suffering from degenerative diseases such as Parkinson's and Alzheimer's as well as debilitating conditions resulting from stroke, neurological damage, and spinal cord injuries. Headquartered in New York, BHI researchers and investigators are conducting safety and efficacy studies on human umbilical cord blood stem cells. Based on Institutional Review Board approved protocols, we are collecting and analyzing clinical data and have been presented the results in several scientific publications. The Food and Drug Administration (FDA) endorsed our Investigator-led IND (Investigational New Drug) application to allow for initiation of a clinical study of an FDA-approved cell therapy (Hematopoietic Progenitor Cell (HPC), cord blood) for treatment of acute ischemic stroke. We are currently working on submission of an IND application to allow for initiation of a clinical study of an FDA-approved cell therapy HPC, cord blood for the treatment of knee osteoarthritis associated pain. Other follow-on indications would be for treatment of diabetes type 2. Our mission is three-pronged and includes philanthropy through our charitable foundation, research and development, and clinical application. BHI Therapeutic Sciences has assembled a team of industry leading experts to deliver high-quality care, including highly skilled scientists and physicians.